Lymphoma of the skin: newer targeted and immune drugs worked in 34% to 69% of patients
A meta-analysis of 41 studies, published Oct. 28, 2026, in JAMA Dermatology, found that response rates to targeted and immune-based drugs for cutaneous T-cell lymphoma ranged widely, led by brentuximab vedotin at…